ArticleDiscover oncology2025
Trends and hotspots in targeted therapy resistance research for renal cell carcinoma: a bibliometric and visualization analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The emerging role of oncolytic virotherapy in genitourinary malignancies.Frontiers in cell and developmental biology · 2026Review
- Oncolytic adenoviruses in bladder and kidney cancers: emerging strategies and next frontiers.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMolecular targeted therapies have shown considerable efficacy in treating metastatic renal cell carcinoma (mRCC). However, many patients still experience tumor recurrence or metastasis due to drug resistance. Despite extensive research on resistance mechanisms, there is a lack of comprehensive bibliometric studies examining the overall characteristics of targeted therapy resistance in renal cell carcinoma. MATERIALS AND
methodsPublications on resistance to targeted therapy in renal cell carcinoma were identified from the Web of Science Core Collection (WoSCC) from June 2004 to November 2024. The English-language literature was analyzed using bibliometric tools, including VOSviewer and CiteSpace, to examine publication trends, active countries/regions, key authors, and institutions. Keyword analysis, co-citation mapping, and gene identification were conducted to uncover research trends and focal points.
resultsA total of 1081 publications were identified, with the United States, China, and Italy as the top contributing countries. Prominent institutions included the Cleveland Clinic, the Sloan Kettering Cancer Center, the MD Anderson Cancer Center, Fudan University, and Huazhong University of Science and Technology. Camillo Porta was a prolific author, and Brian I. Rini was among the most highly cited. The journal Cancers published the most papers in this field, and the Journal of Clinical Oncology was the most co-cited. Key research topics included the "tumor microenvironment" and "combination therapy". A comprehensive analysis of publications related to "the tumor microenvironment" reveals that "renal cancer stem cells" and "epithelial-mesenchymal transition" have been identified as key terms strongly associated with therapeutic resistance mechanisms in targeted cancer treatments. In-depth analysis of the regulatory molecules and molecular mechanisms in the literature highlighted the roles of microRNA and the synergistic effects between anti-PD-L1/PD-1 and targeted drugs.
conclusionsBibliometric analysis of research on molecular targeted therapy resistance in renal cell carcinoma revealed a clear trajectory and rapidly increasing trend in this field. The impact of the tumor microenvironment, particularly the roles of renal cancer stem cells and epithelial-mesenchymal transition, has garnered significant attention. Additionally, the combination of anti-PD-L1/PD-1 and targeted drugs, as well as the involvement of miRNA, have emerged as key areas of focus. As understanding of this field deepens, future research is expected to uncover novel therapeutic targets and more effectively overcome the challenges of targeted therapy resistance in renal cell carcinoma, ultimately improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.